Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Revenue projections:

Investors may be wary of GILD as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio	1.265000
forwardPE	14.888672
debtToEquity	223.465000
earningsGrowth	0.000000
revenueGrowth	0.102000
grossMargins	0.796040
operatingMargins	0.336790
trailingEps	-2.610000
forwardEps	9.935070

Gilead Sciences, Inc.'s current ratio of 1.265 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. Gilead Sciences, Inc.'s ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
GILD's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
Gilead Sciences, Inc.'s elevated debt-to-equity ratio reflects a high level of debt relative to equity, signaling that the company is heavily leveraged. This reliance on debt could increase financial risk in periods of economic uncertainty.
GILD's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.

Price projections:

GILD's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about GILD's ability to grow.

Insider Transactions:

There were 33 GILD sales transactions, at market price of 131.2932988947088.During the review period, no sell transactions were executed.Investors have shown more interest in buying than selling GILD at current price levels, which may point to a positive market sentiment. This could indicate that investors are expecting favorable results from the stock in the near future.

Recommendation changes over time:

Analysts' recent buy bias toward GILD suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see GILD as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.